Conference Day One |
Tuesday, December 2, 2025
8:00 am Registration & Coffee
8:50 am Chair’s Opening Remarks
9:00 am The Complement Advisory Board Fireside Chat: An Overview of the Complement Therapeutics Landscape
Synopsis
- Discussing the dynamic landscape of complement drug development, exploring novel targets and diverse therapeutic modalities and their potential across various diseases, including kidney, CNS, and ophthalmology
- Addressing critical operational and clinical challenges in complement therapy, delivery, and oral formulations
- Focussing on the scientific and translational hurdles that remain, covering the importance of developing robust biomarkers, predictive models the promising role of complement inhibitors in combination therapies
Highlighting Clinical Progress in Complement Therapeutics & Uncovering Learnings from Nephrology, Ophthalmology & Hematology to Inform Future Clinical Success
9:30 am Harnessing Clinical Success in Complement-Mediated Kidney Diseases to Inform Wider Complement-Mediated Indications
Synopsis
- Exploring the role of C3 fragments in the kidney in pathogenesis of C3G and other kidney disease
- Efficacy of C3/C3b inhibition in C3G patients
- Understanding the impact of C3/C3b inhibition on complement deposits in the kidney of C3G patients
10:00 am Reviewing the Advancements of siRNA-based Therapeutics to Treat Complement-Mediated Kidney Disease
Synopsis
- Highlighting the potential of RNA interference-based therapeutics in modulating complement-driven kidney diseases and offer insights into their mechanism of action
- Exploring the unique advantages of siRNA technology for complement inhibition in kidney disease, such as potentially targeted delivery and sustained effect
- Touching upon challenges and best practices in conducting large Phase 3 trials
10:30 am Panel Discussion: Navigating the Clinical Challenges as Complement Inhibitors are Applied to Larger Patient Populations
Synopsis
- Discussing the critical considerations for managing systemic complement inhibition and minimizing off-target effects and infection risks in a diverse patient cohort
- Overcoming diagnostic and biomarker limitations to accurately identify which patients within larger populations will truly benefit from complement inhibition
- Exploring innovative drug delivery modalities are essential to improve patient convenience and adherence for chronic use in larger populations
11:00 am Speed Networking
Synopsis
Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in the complement field. Establish meaningful connections and gain individual insight beyond the papers and press releases into the pioneering research and technique applications.
11:30 am Morning Break & Networking
Unlocking the Role of Complement Biomarkers in Diagnostic & Efficacy Monitoring to Unlock Novel Disease Insights
12:00 pm New Frontiers in Complement Imaging for Accurate Assessment of Activated Proteins within the Cascade
Synopsis
- Identifying and validating immune-related blood-based biomarkers to serve as reliable read-outs for complement mediated diseases
- Delving into the complexities of discovering, developing, and validating biomarkers that accurately reflect the efficacy of complement-targeting drugs
- Focussing on generalized markers of complement activation an inflammation the retain relevancy across various conditions, moving beyond organ-specific structural biomarkers
12:30 pm Session Reserved for National Jewish Health
12:40 pm Complement-Neutrophil Axis: Drivers of Neuroinflammation & Tissue Injury
Synopsis
- Explaining how complement activation products like C5a attract and activate neutrophils, creating a key inflammatory axis
- Detailing how the complement-neutrophil interaction fuels neuroinflammation, leading to the release of pro-inflammatory mediators
- Connecting this sustained neuroinflammation to direct tissue damage in various neurological disorders
12:50 pm Session Reserved for Machaon Diagnostics
1:00 pm Lunch & Networking
2:00 pm Visualization of Complement Activation in the Eye & Choroidal Capillaries as a Reliable Biomarker of Complement Activation
Synopsis
- Exploring advanced imaging and molecular probes to visualize complement activation in the eye and choroidal capillaries non-invasively and in real-time
- Showing how visualizing choroidal complement can reliably indicate disease progression and treatment response in ocular conditions
- Discussing how this visualization approach can guide patient stratification, monitor drug efficacy, and inform personalized treatments for complement-driven eye diseases
Uncovering Novel Indications in the Complement Field & Navigating the Expansion into Autoimmunity, Oncology & Non-Rare Diseases
2:30 pm The Oral C5aR Inhibitor INF904 for the Treatment of Chronic Inflammatory Diseases & Beyond
Synopsis
- INF904 – C5aR inhibitor with best-in-class potential
- C5aR inhibition in Hidradenitis Suppurativa
- C5aR inhibition in Chronic Spontaneous Urticaria
3:00 pm Discussing the Impact of Complement Activation on Neutrophils & Their Role in Autoimmune & Inflammatory Disorders
Synopsis
- Highlighting the critical role of neutrophils as downstream effectors impacted by complement activation
- Understanding how complement influences neutrophil behaviours and activation and how targeting this interface could offer novel therapeutic avenues beyond the complement cascade’s identified proteins
- Exploring the targets that neutrophils are important in, focusing on Cystic Fibrosis and type 1 diabetes
3:30 pm Afternoon Refreshments & Poster Session
Synopsis
Immerse yourself in an engaging and informal session and join your peers in a relaxed atmosphere that encourages meaningful conversations and discussions. Explore a range of exciting poster presentations and showcase your own developments in the complement-based therapeutics world. Don’t miss out on the chance to submit your own poster and learn, and present. To submit your poster please contact info@hansonwade.com
4:00 pm Discovering Granzyme K as a Potential 4th Complement Pathway
Synopsis
- Granzyme K as an activator of the complement cascade through the cleavage of C2 and C4 proteins
- Detailing the specific biomarker strategy employed in Empasiprubart trials for MMN, highlighting how these markers are used to assess disease activity, predict treatment response, and monitor therapeutic impact
- Exploring the implications of the biomarker strategy for future clinical practice, discussing how these insights could lead to more precise patient selection, personalized dosing, and improved long-term management of MMN
4:30 pm Empasiburbart for MMN: Clinical Update & Biomarker Strategy
Synopsis
- Outlining a comprehensive clinical update on Empasiprubart’s performance in treating MMN, including key efficacy data, patient outcomes, and safety profile from ongoing trials
- Initiating the full complement pathway, generating inflammatory molecules like C3a, C5a, opsonins, and the membrane attack complex
- Highlighting GZMK as a previously unrecognized and important contributor to tissue inflammation across various diseases, suggesting its potential as a novel therapeutic target